

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
Details : Gadoterate Meglumine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 10, 2020
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Dipan Shah
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dotarem is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 20, 2017
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Dipan Shah
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years
Details : Dotarem is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 08, 2015
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dotarem (Gadoterate Meglumine) is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Neoplasms.
Product Name : Dotarem
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 13, 2014
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gadoterate Meglumine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
March 07, 2013
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Dialysability of Dotarem® in Dialysed Patients
Details : Dotarem is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 10, 2011
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
Details : Dotarem (Gadoterate Meglumine) is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Central Nervous System Diseases.
Product Name : Dotarem
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 30, 2010
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
